Roger Storms - Puma Biotechnology Senior Sales
| PBYI Stock | USD 7.10 0.28 4.11% |
Executive
Roger Storms is Senior Sales of Puma Biotechnology
| Address | 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 |
| Phone | 424 248 6500 |
| Web | https://www.pumabiotechnology.com |
Puma Biotechnology Management Efficiency
The company has return on total asset (ROA) of 0.099 % which means that it generated a profit of $0.099 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3969 %, meaning that it created $0.3969 on every $100 dollars invested by stockholders. Puma Biotechnology's management efficiency ratios could be used to measure how well Puma Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Puma Biotechnology's Return On Tangible Assets are increasing as compared to previous years. The Puma Biotechnology's current Return On Capital Employed is estimated to increase to 0.25, while Return On Assets are projected to decrease to 0.13. As of now, Puma Biotechnology's Debt To Assets are increasing as compared to previous years. The Puma Biotechnology's current Fixed Asset Turnover is estimated to increase to 42.75, while Total Assets are projected to decrease to under 168.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Carl Denny | Abeona Therapeutics | N/A | |
| Paul Little | Eledon Pharmaceuticals | 61 | |
| Alison Moore | Allogene Therapeutics | 57 | |
| Joe Oriti | Sagimet Biosciences Series | N/A | |
| Jared JD | Entrada Therapeutics | N/A | |
| David JD | Allogene Therapeutics | 54 | |
| Lisa Molyneux | Humacyte | N/A | |
| Jayanthi Wolf | Atea Pharmaceuticals | N/A | |
| SPHR GPHR | Humacyte | N/A | |
| Heather Connelly | Humacyte | N/A | |
| Susan Lundeen | Allogene Therapeutics | 60 | |
| Jonae Barnes | Atea Pharmaceuticals | N/A | |
| Robert DUrso | Sagimet Biosciences Series | N/A | |
| Yinlin Chen | Allogene Therapeutics | N/A | |
| Barbra Sasu | Allogene Therapeutics | N/A | |
| George Kemble | Sagimet Biosciences Series | 63 | |
| Benjamin Beneski | Allogene Therapeutics | 49 | |
| Kevin Healy | Entrada Therapeutics | N/A | |
| Keith Pietropaolo | Atea Pharmaceuticals | N/A | |
| Earl Esq | Allogene Therapeutics | 63 | |
| Sabrina Osborne | Humacyte | N/A | |
Management Performance
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.099 |
Puma Biotechnology Leadership Team
Elected by the shareholders, the Puma Biotechnology's board of directors comprises two types of representatives: Puma Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Puma. The board's role is to monitor Puma Biotechnology's management team and ensure that shareholders' interests are well served. Puma Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Puma Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Ludwig, Chief Officer | ||
| Roger Storms, Senior Sales | ||
| Maximo Nougues, CFO Officer | ||
| Alan Auerbach, Founder, Chairman, CEO and President Secretary and Member of Stock Option Committee | ||
| Alvin Pharmd, Chief Officer | ||
| Heather Blaber, Senior Marketing | ||
| FRAPS BSc, Pharmacovigilance, Affairs | ||
| Mariann Ohanesian, Senior Director, Investor Relations | ||
| Bo Chao, Senior Development |
Puma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Puma Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.099 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 270.68 M | ||||
| Shares Outstanding | 50.39 M | ||||
| Shares Owned By Insiders | 15.38 % | ||||
| Shares Owned By Institutions | 71.40 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | 18.52 X |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.78 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.